NO20090333L - Fremgangsmater og preparater rettet mot hepsin - Google Patents

Fremgangsmater og preparater rettet mot hepsin

Info

Publication number
NO20090333L
NO20090333L NO20090333A NO20090333A NO20090333L NO 20090333 L NO20090333 L NO 20090333L NO 20090333 A NO20090333 A NO 20090333A NO 20090333 A NO20090333 A NO 20090333A NO 20090333 L NO20090333 L NO 20090333L
Authority
NO
Norway
Prior art keywords
methods
directed against
preparations directed
against hepsin
hepsin
Prior art date
Application number
NO20090333A
Other languages
English (en)
Norwegian (no)
Inventor
Daniel K Kirchhofer
Rajesh Vij
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20090333L publication Critical patent/NO20090333L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20090333A 2006-06-22 2009-01-21 Fremgangsmater og preparater rettet mot hepsin NO20090333L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80558906P 2006-06-22 2006-06-22
PCT/US2007/071688 WO2007149932A2 (fr) 2006-06-22 2007-06-20 Procédés et compositions pour cibler l'hepsine

Publications (1)

Publication Number Publication Date
NO20090333L true NO20090333L (no) 2009-03-23

Family

ID=38754528

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090333A NO20090333L (no) 2006-06-22 2009-01-21 Fremgangsmater og preparater rettet mot hepsin

Country Status (16)

Country Link
US (2) US8124352B2 (fr)
EP (1) EP2044124A2 (fr)
JP (1) JP2009540835A (fr)
KR (1) KR101410195B1 (fr)
CN (1) CN101490088B (fr)
AU (1) AU2007260950B2 (fr)
BR (1) BRPI0712273A8 (fr)
CA (1) CA2656168A1 (fr)
IL (1) IL195561A (fr)
MX (1) MX2008015882A (fr)
MY (1) MY150643A (fr)
NO (1) NO20090333L (fr)
NZ (1) NZ573178A (fr)
RU (1) RU2009101813A (fr)
WO (1) WO2007149932A2 (fr)
ZA (1) ZA200810225B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831370A4 (fr) 2004-12-13 2009-08-12 Alethia Biotherapeutics Inc Sequences polynucleotidiques et polypeptidiques participant au remodelage osseux
WO2007149932A2 (fr) 2006-06-22 2007-12-27 Genentech, Inc. Procédés et compositions pour cibler l'hepsine
JP5819308B2 (ja) 2009-10-22 2015-11-24 ジェネンテック， インコーポレイテッド マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
RU2559533C2 (ru) 2009-10-22 2015-08-10 Дженентек, Инк. Антитела против гепсина и способы их применения
PL2542576T3 (pl) 2010-03-02 2016-10-31 Sposoby badań przesiewowych przeciwciał
WO2011161189A1 (fr) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anticorps anti-hepsine et leurs procédés d'utilisation
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
KR101972446B1 (ko) * 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
WO2017162659A1 (fr) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Hepsine intracellulaire en tant que cible thérapeutique pour le traitement du cancer à l'aide d'une amplification de centrosomes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282198B2 (en) 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US6268165B1 (en) 1997-03-19 2001-07-31 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US5981830A (en) * 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
EP1252300B1 (fr) 2000-02-03 2011-01-19 Dendreon Corporation Molecules d'acides nucleiques codant pour des proteases a serine transmembranaires, proteines codees et procedes associes
US6423543B1 (en) * 2000-12-20 2002-07-23 Isis Pharmaceuticals, Inc. Antisense modulation of hepsin expression
CA2432991A1 (fr) 2001-01-23 2002-08-01 Irm, Llc Genes surexprimes dans des maladies de la prostate servant de cibles diagnostiques et therapeutiques
AU2002240336A1 (en) 2001-02-14 2002-08-28 Tularik Inc. Methods for the diagnosis and treatment of tumors employing the hepsin gene
US6482630B2 (en) * 2001-03-29 2002-11-19 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20030113762A1 (en) * 2001-08-17 2003-06-19 Warrington Janet A. Gleason grade 4/5 prostate cancer genes
US20040009911A1 (en) * 2002-01-31 2004-01-15 Irm, Llc Hepsin substrates and prodrugs
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
JP3775346B2 (ja) * 2002-05-29 2006-05-17 株式会社日立製作所 テレビ電話システムおよびその端末装置
WO2004009803A2 (fr) 2002-07-23 2004-01-29 Bayer Healthcare Ag Regulation de l'hepsine humaine
US6977170B2 (en) 2002-09-06 2005-12-20 Applera Corporation Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof
US20040132156A1 (en) * 2002-10-04 2004-07-08 Schering Aktiengesellschaft Modified hepsin molecules having a substitute activation sequence and uses thereof
MX2007001064A (es) 2004-07-26 2007-04-12 Genentech Inc Metodos y composiciones para modular la activacion del factor de crecimiento de hepatocitos.
WO2007149932A2 (fr) 2006-06-22 2007-12-27 Genentech, Inc. Procédés et compositions pour cibler l'hepsine
AU2007260953B2 (en) * 2006-06-22 2013-07-11 Genentech, Inc. Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator
RU2559533C2 (ru) * 2009-10-22 2015-08-10 Дженентек, Инк. Антитела против гепсина и способы их применения

Also Published As

Publication number Publication date
US20120141374A1 (en) 2012-06-07
RU2009101813A (ru) 2010-07-27
MX2008015882A (es) 2009-01-12
KR20090029276A (ko) 2009-03-20
NZ573178A (en) 2012-02-24
CA2656168A1 (fr) 2007-12-27
JP2009540835A (ja) 2009-11-26
AU2007260950A8 (en) 2009-01-22
WO2007149932A3 (fr) 2008-05-02
US8383123B2 (en) 2013-02-26
US8124352B2 (en) 2012-02-28
KR101410195B1 (ko) 2014-06-19
AU2007260950B2 (en) 2011-09-15
BRPI0712273A8 (pt) 2019-01-22
ZA200810225B (en) 2010-03-31
MY150643A (en) 2014-02-14
CN101490088B (zh) 2015-04-08
EP2044124A2 (fr) 2009-04-08
BRPI0712273A2 (pt) 2012-03-06
IL195561A0 (en) 2011-08-01
US20100021474A1 (en) 2010-01-28
CN101490088A (zh) 2009-07-22
WO2007149932A2 (fr) 2007-12-27
IL195561A (en) 2013-04-30
AU2007260950A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
NO20084356L (no) Anti TAT226-antistoffer og immunokonjugater
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
HUS2300026I1 (hu) Anti-CTLA-4 ellenanyag készítmények
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
NO20090333L (no) Fremgangsmater og preparater rettet mot hepsin
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
MY148763A (en) Anti-5t4 antibodies and uses thereof
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
LT3421498T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
NO20083609L (no) Fremgangsmater og sammensetninger for malrettet-RELT
DK1768691T3 (da) Aequorinholdige præparater og fremgangsmåder til anvendelse af samme
WO2006031831A3 (fr) Techniques de detection de cancer ovarien
ES1058780Y (es) Brida de union autoblocante.
WO2007002096A3 (fr) Methodes et compositions permettant de cibler ifnar2
CR20140126A (es) Anticuerpos anti-tat226 e inmunoconjugados
TH148531A (th) วิธีการและองค์ประกอบสำหรับกำหนดเป้าหมายพอลิยูไบควิทิน
EP1929033A4 (fr) Anticorps modifiant le cancer
TR200602530U (tr) Kılavuz ipe dizili boncuk
EP1915455A4 (fr) Anticorps modifiant le cancer
HK1109639A (en) Anti-ephb2 antibodies and methods using same
HK1118932A (en) Anti-ox40l antibodies and methods using same
HK1113802A (en) Anti-trkb monoclonal antibodies and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application